Dutch investment firm Life Sciences Partners BV, or LSP, corralled more than €750 million in capital commitments across three investment vehicles.

The fundraising took 10 months, and the proceeds will be used to finance European drug-development and medical-technology companies.

New and existing investors include blue-chip insurance companies, pension funds, government funds, asset managers, family offices and big pharmaceutical enterprises.

The life sciences- and healthcare-focused funds consist of LSP 6, LSP Health Economics Fund 2 and LSP Life Sciences Fund.

LSP 6 will target early- to late-stage drug- and technology-development companies. It has collected over €410 million of capital and is still open for commitments.

LSP Health Economics Fund 2 will focus on late-stage medical-technology companies and secured €280 million of capital in its final close in December 2017.

LSP Life Sciences Fund will invest in publicly listed small- to mid-cap healthcare companies. It has raised about €200 million of capital, together with several related funds.